Eli Lilly expands manufacturing for oral obesity treatment as adoption grows

CEO David Ricks said the company is expanding manufacturing capacity for its new oral obesity treatment, adding that it is gaining ground among patients starting GLP-1 pills. Ricks told CNBC that Foundayo accounts for roughly one-third of new oral GLP-1 prescriptions.